Sun, moon, stars, and rivers, with friendly lights, summer rain and winter snow, coexisting in the north and south. On November 30, 2022, the North South Joint Clinical Application Practice Forum of "Integrating Zhenzhi Shengbai Oral Liquid (Mixture)" was held in the cloud, hosted by Hubei Mengyang Pharmaceutical Co., Ltd.

This meeting was chaired by Professor Cui Xiaonan from the First Affiliated Hospital of Dalian Medical University, and presided over by Professor Yin Liangwei from the Central Hospital of Dalian. Professors Hu Hong and Wen Shenglan from the Run Run Run Shaw Hospital of Zhejiang University School of Medicine, Chen Yamin and Gao Ping from the First Affiliated Hospital of Dalian Medical University, Chen Zhiming from the Oncology Hospital of Shantou University School of Medicine, and Zhu Yanhua from the Central Hospital of Dalian University were also present, Professor Cao Yang from Dalian Chengda Wenxi Cancer Hospital, Professor Qu Hongjun from Yingkou Economic and Technological Development Zone Central Hospital, Professor Qi Jing from Yingkou Fangda Hospital, Professor Wang Licheng from Heilongjiang Second Hospital, Professor Zhang Nan and Professor Wang Chunyan from Jilin University First Hospital, and Professor Xu Zhongling from the Third Affiliated Hospital of Qiqihar Medical College Professor He Xin and many other experts conducted in-depth discussions on the mechanism and clinical rational use of Shengbai oral liquid (mixture). The conference had a strong academic atmosphere and received praise from the attending experts.

 会议伊始，崔晓楠教授对生白口服液（合剂）临床疗效表达了认可，同时隆重介绍了会议主持人尹良伟教授，由尹良伟教授进行了本次会议的主持。

During the meeting, Professor Hu Hong gave a detailed introduction to the mechanism of action and clinical rational use of Shengbai oral liquid (mixture), and affirmed its use as a basic medication for leukopenia caused by cancer radiotherapy and chemotherapy. Professor Chen Yamin, Professor Chen Zhiming, and Professor Wen Shenglan have all expressed their recognition of the mechanism of action, clinical efficacy, and academic value of Shengbai oral liquid (mixture) based on their clinical medication experience. At the same time, they believe that the combination of traditional Chinese and Western medicine can better improve the quality of life of cancer patients.

Following the case sharing article, two cases of patients with leukopenia caused by chemotherapy using Shengbai oral liquid (mixture) were shared and commented on. If there is leukopenia during treatment, timely application of Shengbai oral liquid (mixture) can effectively reduce the degree of leukopenia, ensure the smooth completion of radiotherapy and chemotherapy, and have significant implications for improving the patient's physical signs. In the subsequent comment and discussion section, experts expressed their own opinions and gave high praise to the treatment of leukopenia and cancer-related fatigue with Shengbai oral liquid (mixture).

At the end of the meeting, Professor Cui Xiaonan made a summary of the meeting. Professor Cui pointed out that the traditional Chinese medicine treatment of bone marrow suppression represented by Shengbai oral liquid (mixture) is a combination of innate and acquired tonics, which is a reconstruction of hematopoietic function, immune function, repair function, and the entire bone marrow soil. At the same time, Professor Cui thanked Mengyang Pharmaceutical and all the attending experts. We look forward to everyone contributing to the development of cancer treatment together, and also look forward to the early resolution of the epidemic. Let's meet again offline!